Global Preclinical Imaging Industry Insights and 2018 Forecast Report

Global Preclinical Imaging Market 2015-2019 is the latest addition to Sandlerresearch.org industry research reports collection. 

Pre-clinical Imaging is in vivo imaging of small animals, which had been progressively deployed in drug development process. It helps in the visualizing and monitoring of animals for research with respect to tissue, organ, cell (at molecular level), and physiological and environmental changes. One of the main application areas of pre-clinical imaging is early detection of diseases. Currently the most used imaging modalities are optical (fluorescence and bioluminescence), PET, and MRI. In addition, multi-modalities such as PET+CT and SPECT+CT are the most used imaging combinations. In vivo imaging is increasingly used in target identification, compound optimisation and pre-Phase I studies, and in the drug development process. Thus, it bridges the gap between in vitro exploratory and in vivo clinical research.

Analysts forecast the Global Pre-clinical Imaging market to grow at a CAGR of 15.02 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and growth prospects of the Global Pre-clinical Imaging market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of pre-clinical imaging systems. Pre-clinical imaging systems can be segmented based on the type of equipment, as mentioned below:

• Micro MRI
• Micro-PET
• Micro-CT
• PAT
• SPECT
• Multi-modality
• Optical Imaging
• Ultrasound

The report presents the vendor landscape and a corresponding detailed analysis of the top seven vendors in the Global Pre-clinical Imaging market. The vendor landscape in this report focuses on the vendors that provide access to new and technologically advanced pre-clinical imaging systems. The report also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.

Global Pre-clinical Imaging Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Pre-clinical Imaging market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Single User License of the Report is Available at USD 2500, Buy the Report @ http://www.sandlerresearch.org/purchase?rname=29581 .

Worldwide Biologic Therapeutics Industry Segments Growth: Protein therapeutics, Vaccines, Cell therapy

Biologic therapeutics include virus, therapeutic serum, toxin, allergenic product, antitoxin, blood component or derivative, vaccine, blood, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), intended for the prevention, treatment, or cure of a disease or condition. These products differ from small molecules in terms of molecular weight, structure, synthesis, and immunogenicity. Biologic products are generally characterized by high molecular weight and complex structures. These products are usually derived from living entities and are less easily characterized compared to small molecules. These products are often susceptible to extreme temperatures and light.

Analysts forecast the Global Biologic Therapeutics market to grow at a CAGR of 8.22 percent over the period 2013-2018.

The report recognizes the following companies as the key players in the Global Biologic Therapeutics Market: Amgen Inc., F. Hoffmann-La Roche Ltd., Novo Nordisk A/S and Sanofi SA.

Other Prominent Vendors in the market are: Abbvie, AstraZeneca, Bavarian Nordic, Baxter International, Beijing Minhai Biotechnology, Bharat Biotech, Bharat Immunologicals and Biologicals, bioCSL, Biodel, Bio Med, Bristol-Myers Squibb, Diamyd Medical, DiaVacs, Dynavax Technologies, Eli Lilly, Generex Biotechnology, Hualan Biological Engineering, Imunoloski Zavod, Indian Immunologicals, Janssen Pharmaceuticals, JN International Medical, Kaketsuken, LG Life Sciences, Macrogenics, MannKind, Merck, Mitsubishi Tanabe Pharma, Nuron Biotech, Osiris Therapeutics, Pfizer, Protalix, Protein Sciences, Serum Institute of India, Shenzhen Kangtai Biological Products, Sinovac Biotech, Tolerion, Vacunas Finlay, XOMA and Zydus Cadila.

One key trend upcoming in this market is the emergence of targeted therapies, which are generally associated with better efficacy and safety compared to traditional drugs. Thus, these drugs are expected to increase patient compliance and fuel the market.

Get discount on the Report @ http://www.sandlerresearch.org/discount?rname=26232 .

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Biologic Therapeutics market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of the following drugs:

• Protein therapeutics (monoclonal antibodies, enzymes, and other protein therapeutics)
• Vaccines (pediatric vaccines and adult vaccines)
• Cell therapy

The Other Protein Therapeutics segment covers proteins such as cytokines, fusion proteins, peptide antibiotics, peptide hormones, and blood factors.

Global Biologic Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Biologic Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

According to the report, an aging population is one of the major drivers of the market. An increase in the aging population is expected to increase the population of patients suffering from a variety of diseases, and thereby drive the market.

Further, the report states that the need for cold storage is one of the major challenges in the market. Cold storage increases the transportation and storage costs of the therapeutic products, thereby adding to the final cost of the products.

Single User License of the Report is Available at USD 3500, Buy the Report @ http://www.sandlerresearch.org/purchase?rname=26232 .

Global Analysis - Pharmaceuticals Industry Fact Book 2014

World Pharmaceuticals Factbook 2014 is the latest addition to Reportsnreports.com industry research reports collection.

The newly updated World Pharmaceuticals Fact Book 2014 is the must-have source of thousands of facts, figures and statistics for 72 pharmaceuticals markets worldwide!

Now including analysis trends for 2009-2014 this reports looks at market value at a world, regional and country level, healthcare infrastructure data, GDP & healthcare spending and key demographic trends.

With the World Pharmaceuticals Fact Book 2014, you will have the answers to key market questions such as:

Which country spends most on pharmaceuticals as a % of GDP?How are the economic downturn and currency fluctuations affecting expenditure in key markets?Which pharmaceutical sectors are growing the fastest and where?What have been the key trends affecting pharmaceutical companies in leading emerging markets such as India, China, Brazil and Russia?How does the Brazilian market compare with Mexico and Argentina in terms of total health expenditure?What demographic development is affecting the market in Central and Eastern Europe?

Get discount on the Report @ http://www.reportsnreports.com/contacts/Discount.aspx?name=298385 .

Over 25,000 data points at your fingertips – providing:

Key economic, demographic and health statistics on 72 markets around the worldFive years of historical data for markets, GDP & healthcare spending, demographics and healthcare statisticsWorld/regional overviews plus statistics on individual countriesOver 500 tables and charts delivered in a single PDF reportPLUS an additional interactive data tool included in the price, where you can segment, compare and export the data in any way that you wish, to suit your information needs

Single User License of the Report is Available at USD 1545, Buy the Report @ http://www.reportsnreports.com/Purchase.aspx?name=298385 .

The regions used in the report are:

Americas: Argentina, Brazil, Canada, Chile, Colombia, Cuba, Mexico, Peru, USA, Venezuela
Asia/Pacific: Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam
Eastern Europe: Belarus, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Turkey, Ukraine
Middle East/Africa: Egypt, Ghana, Iran, Iraq, Israel, Jordan, Kenya, Morocco, Nigeria, Oman, Qatar, Saudi Arabia, South Africa, UAE
Western Europe: Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, UK

Inquire Before buying the Report @ http://www.reportsnreports.com/contacts/InquiryBeforeBuy.aspx?name=298385 .

Contact sales@reportsandreports.com / Call +1 888 391 5441 for further information on “World Pharmaceuticals Factbook 2014” report OR for any other market research and intelligence needs you may have for your business.

Erectile Dysfunction Drugs Market Profiles for Apricus, Bayer, Pfizer and Others Analyzed

A man’s failure to sustain an erection that is adequate enough for sexual activity is known as erectile dysfunction. It also refers to the inconsistency to do so, or the inability to endure it for an extended period. Erectile dysfunction can be due to a number of reasons including aging, high blood pressure, diabetes mellitus, depression, smoking, nerve or spinal cord damage, alcoholism, and low testosterone levels. Treatments for erectile dysfunction include adopting a healthy lifestyle, oral phosphodiesterase type 5 (PDE5) inhibitors, vacuum devices, and surgery. Erectile dysfunction affects the quality of life and leads to stress, anxiety, and self-confidence problems. New research is undergoing in the field of erectile dysfunction to find more enhanced and effective therapies.

Analysts forecast the Global Erectile Dysfunction Drugs market to decline at a CAGR of 4.47 percent over the period 2013-2018.

The Report recognizes the following companies as the key players in the Global Erectile Dysfunction Drugs Market: Apricus Biosciences Inc., Bayer AG, Dong-A Socio Holdings Co. Ltd., Eli Lily & Co., Pfizer Inc. and Vivus Inc.

Other Prominent Vendors in the market are: Auxillium Pharmaceuticals, Cristalia Produtos Quimicos Farmaceuticos, Futura Medical, Johnson & Johnson, Meda Pharmaceuticals, Pacific Therapeutics and Seattle Genetics.

One of the emerging trends in this market is an increase in awareness of erectile dysfunction. The acceptability of erectile dysfunction drugs is expected to increase owing to increasing public awareness about erectile dysfunction and the need to treat it.

Get discount on the Report @ http://www.sandlerresearch.org/discount?rname=23077 .

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Erectile Dysfunction Drugs market for the period 2014-2018. The Global Erectile Dysfunction Drugs market can be divided into six segments: PDE 5 Inhibitors, Vacuum Constriction Device, Penile Prosthesis, Vascular Reconstructive Surgery, Injection Therapies, and Testosterone Replacement Therapy. To calculate the market size, the report considers the revenue generated from the sales of various drugs and topical creams used for the treatment of erectile dysfunction.

Global Erectile Dysfunction Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Erectile Dysfunction Drugs market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

According to the report, one of the main drivers in the market is the increase in aging population. The number of patients suffering from erectile dysfunction is growing owing to increasing aging population both in developing and developed countries.

Further, the report states that one of the main challenges in the market is the high cost of erectile dysfunction drugs. Despite numerous benefits, the high cost of erectile dysfunction drugs hinders acceptability among patients. Many patients do not have the required budget for investing in high-cost treatment options.

Single User License of the Report is Available at USD 2500, Buy the Report @ http://www.sandlerresearch.org/purchase?rname=23077 .

Worldwide Pneumococcal Vaccines Industry Trends Challenges and Key Vendors Analysis Report 2018

Pneumococcus (Streptococcus pneumonia), a pathogenic bacterium, is the leading cause of serious illness across the globe. It is the main cause of pneumonia, sinusitis, blood infections, meningitis, and middle ear infections (otitis media). Pneumococcal disease affects children and the elderly, and it is one of the leading infectious diseases worldwide. It kills almost 1.6 million people (including more than 800,000 children under the age five years) every year. Pneumococcal disease can be prevented by vaccination. Vaccination involves the introduction of dead or weakened antigen into the human body, which in turn produces lymphocytes to counter the infection and any future invasions by that antigen.

Analysts forecast the Global Pneumococcal Vaccines market to grow at a CAGR of 4.90 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Pneumococcal Vaccines market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of various vaccines administered to actively immunize pneumococcal disease caused by different serogroups of Streptococcus pneumonia.

Global Pneumococcal Vaccines Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Pneumococcal Vaccines market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Single User License of the Report is Available at USD 2500, Buy the Report @ http://www.sandlerresearch.org/purchase?rname=23070 .

Worldwide Non-small Cell Lung Cancer Industry Segments Growth: Biologics and Small Molecules

Non-small cell lung cancer occurs when normal cells grow and multiply without control after undergoing a cell transformation. Lung cancer is the leading cause of cancer deaths worldwide, and the incidence of lung cancer is increasing significantly. Lung cancer is the common cause of mortality and morbidity not only in developed countries but also in developing countries. One of the most common types of lung cancer is non-small cell lung cancer. It grows and spreads quite slowly. Smoking is considered as a major cause of lung cancer, although lung cancer also occurs in non-smokers. There are three main types of non-small cell lung cancer: squamous cell (epidermoid) carcinoma, adenocarcinoma, and large cell (undifferentiated) carcinoma. Some of the common symptoms associated with non-small cell lung cancer are chest pain, a cough that does not go away, coughing up blood, fatigue, loss of appetite, losing weight without trying, shortness of breath, and wheezing.

Analysts forecast the Global Non-small Cell Lung Cancer market to grow at a CAGR of 3.62 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Non-small Cell Lung Cancer market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through various therapies adopted for the treatment of non-small cell lung cancer, including

·         Biologics

·         Small Molecules

Global Non-small Cell Lung Cancer Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Non-small Cell Lung Cancer market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Single User License of the Report is Available at USD 2500, Buy the Report @ http://www.sandlerresearch.org/purchase?rname=23071 .

Key Regions

·         Americas

·         APAC

·         EMEA 

Key Vendors

·         AstraZeneca

·         Celgene

·         Eli Lilly

·         F. Hoffmann-La Roche

·         Pfizer

Other Prominent Vendors

·         Aetna

·         Boehringer Ingelheim

·         Celldex

·         Eisai

·         GlaxoSmithKline

·         IMClone

·         Merck Serono

·         Novartis

·         Qiagen

·         OncoGenex

·         OSI Pharmaceuticals

·         Pierre Fabre

·         Sanofi

·         Synta

Get discount on the Report @ http://www.sandlerresearch.org/discount?rname=23071 .